May 25, 2002, Shanghai, China. Porton Pharma Solutions Ltd., one of the world’s leading CDMOs, today celebrated the groundbreaking of its new drug product GMP site. Construction of the facility began this month and will continue in phases until the scheduled completion in the third quarter of 2022.
Built to exacting FDA/EMA standards, the new site will include an OSD clinical supply workshop, an OSD small scale commercial workshop, a High-potent OSD workshop, and an Injection (solution, lyophilization) workshop (isolated).
With this new phase 1, multifunctional GMP site, Porton will also significantly expand its Solubility enhancement (HM, Spray drying) and Complex formulation capabilities and capacities (MUPS, OROS etc. ), marking an even greater improvement in the company’s ability to meet all phases of client drug product manufacturing and supply needs.
About Porton Pharma Solutions Ltd
Founded in July 2005, Porton Pharma Solutions Ltd. (Stock abbreviation: Porton Share; Stock code: 300363) is a leading pharmaceutical CDMO (Contract Development Manufacture Organization) in China.
From its earliest stages of development, Porton has provided global pharmaceutical companies and new drug R&D (Research and Development) institutions with customized R&D.
For further details, visit Porton online: